Besuchen Sie uns auf dem 10. Kongress der Europäischen Akademie für Neurologie, um mehr über unseren datengestützten Ansatz zur Behandlung der Parkinson-Krankheit zu erfahren!

Movement disorders can be especially difficult to diagnose, treat, and understand. In the next 30 years, there will be a strong increase in the number of people affected by movement disorders and that is why we are promoting #MoveDisorder awareness.

A new study on wearable monitoring of negative myoclonus within the home environment is now available. The research was conducted in collaboration between the University of Eastern Finland, Kuopio University Hospital (KUH) - Kuopion yliopistollinen sairaala (KYS), UCL Queen Square Institute of Neurology and Adamant Health.

Meet us at the Neurologipäivät 2023 to learn more about our data-driven approach for managing Parkinson’s disease, and how it will help people with Parkinson’s to get the best treatment possible – improving their quality of life!

Adamant Health is participating in the 96. Kongress der Deutschen Gesellschaft für Neurologie taking place from 8 to 11 November 2023 in Berlin, Germany. Meet us at booth B17 to learn more about our data-driven approach for managing Parkinson’s disease!

A new study by the University of Eastern Finland and Kuopio University Hospital shows that wearable sensor technology can be used to reliably assess the occurrence of myoclonic jerks in patients with epilepsy also in the home environment. The study was carried out by the New Modalities ecosystem funded by Business Finland, with Adamant Health being one partner focusing on software development.